<DOC>
	<DOCNO>NCT00716248</DOCNO>
	<brief_summary>Patients rheumatoid arthritis well control methotrexate plus infliximab may remain remission low disease activity without infliximab . And chance sustain remission increase addition another DMARD , bucillamine , time discontinue infliximab . The BuSHIDO trial prospective , randomize , control study compare MTX monotherapy MTX plus bucillamine combination therapy rate disease flare discontinue infliximab .</brief_summary>
	<brief_title>Bucillamine Study Holding Remission After Infliximab Dose-off</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Bucillamine</mesh_term>
	<criteria>RA accord American College Radiology ( ACR ) classification criterion Age 20 great DAS28ESR &lt; 3.2 DAS28CRP &lt; 2.6 6 month Previously teated bucillamine Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>